MGX logo

METAGENOMI THERAPEUTICS INC

MGXNASDAQ
🏆 #4475 by market capUS Equity
$0.83▲ $0.03 (+4.19%)
Pre-market · at close
🔔
Track MGX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.2%
7d▲ 2.5%
14d▼ 2.0%
30d▼ 26.6%
ytd▼ 48.7%
1y▼ 64.5%
🏦Market Cap
$31M
Small Cap
📈Revenue Growth (YoY)
-50.7%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
1.4x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.80 – $0.83
52-Week Range
$0.75 – $2.94
Volume (shares)
1,665
Avg Volume (shares)
—
Shares Outstanding
37.8M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$25M
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
1.4x
EPS (TTM)
$-2.30
Dividend Yield
—
Dilution (1yr)
+1.4%
MGX logo

METAGENOMI THERAPEUTICS INC

MGX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$25M▼ −51.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
78.9%▼ −21.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$96M▲ +8.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$89M▼ −20.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
37.6M▲ +1.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$1M▲ +$19M YoY
StockOtter · stockotter.space

About METAGENOMI THERAPEUTICS INC

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.